Why #AI-powered Biomarker Analysis is the Future of #Cancer Immune Profiling. Checkpoint inhibitors in #immunotherapy are a major medical breakthrough but scientists & doctors must use AI-powered biomarker analysis for better #immuneprofiling. https://t.co/0hLckxwHRj
Researchers characterize lung inflammation associated with some cancer #immunotherapy: Findings might help predict who will react poorly to certain therapies https://t.co/H3VtX0jZlB
Here's Dr. Andreas Spitzmueller yesterday at #WCLC2019 with his poster: Tumor Proliferation Associated with #Tumor Immunological Status: Study of NSCLC Using Multiplex Immunofluorescence. Thanks to everyone who came by yesterday! https://t.co/Eb82IUgdht
Please join us at @HISTALIM -Multiplex Histopathology Annual Meeting- in Montpellier Sept.12, 2019. Dr. Florian Leiss & Dr. Ana Hidalgo-Sastre will discuss multiplex digital imaging and patient #immuneprofiling! #immunotherapy https://t.co/GjHRd0reIg
See you at @IASLC#WCLC19 in Barcelona this weekend! Please join Dr. Andreas Spitzmueller for his poster presentation: Tumor Proliferation Associated with #Tumor Immunological Status: Study of NSCLC Using Multiplex Immunofluorescence. https://t.co/laXAtnTOvF
Have you read our latest newsletter yet? Don't miss out - find out about our FREE upcoming events before #SITC19, #ESMO19, and meet us at World CB & CDx! Read it here: https://t.co/ogZWWLhnXj #immunotherapy#immunoOncology#biomarkers
See you at @IASLC#WCLC19 in Barcelona this weekend! Please join Dr. Andreas Spitzmueller for his poster presentation: Tumor Proliferation Associated with #Tumor Immunological Status: Study of NSCLC Using Multiplex Immunofluorescence. https://t.co/zD7T3ackwY
#FridayFacts#immunotherapy#DYK- Did you know: mIHC/IF is the most accurate approach in predicting response to anti-PD-1/PD-L1 therapy? Check out this meta-study to compare here:
https://t.co/DPTR64vXzk
During #SITC2019's Workshop on Intratumoral Immunomodulation, the current status of intratumoral immunomodulation will be presented and future directions for the field will be discussed, along with implications for immunotherapy treatments. https://t.co/75fhqdfV4s
The potential and barely tested landscape of combination immunotherapies - birds eye view by Marc Ernstoff, more to come on this from @JaniceM10’s concluding talk on the future of immunotherapy @sitcancer#ACI2019#CLEedition
#ESMO19 Ian Chau (Session Chair) on what to expect from the Keynote Lecture 'Caloric restriction mimetics, autophagy and #cancer' - 30 September at 12:00 https://t.co/RWGdxw27RZ
Attending @HISTALIM -Multiplex Histopathology Annual Meeting- in Montpellier Sept.12, 2019? Please join Dr. Florian Leiss & Dr. Ana Hidalgo-Sastre, who will discuss multiplex digital imaging and patient #immuneprofiling! #immunotherapy https://t.co/3CSe3koQJz
Have you read our latest newsletter yet? Don't miss out - find out about our FREE upcoming events before #SITC19, #ESMO19, and meet us at World CB & CDx! Read it here: https://t.co/5hlxnjVapH #immunotherapy#immunoOncology#biomarkers
Why #AI-powered Biomarker Analysis is the Future of #Cancer Immune Profiling. Checkpoint inhibitors in #immunotherapy are a major medical breakthrough but scientists & doctors must use AI-powered biomarker analysis for better #immuneprofiling. https://t.co/3ajVrlsoqA